Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).

Next Previous
X
Search
Trial Profile

Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Feb 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Renal failure; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms BEACON
  • Sponsors Reata Pharmaceuticals

    • Most Recent Events

    • 11 Oct 2019 According to a Reata Pharmaceuticals media release, results of a post hoc analysis of this trial will be presented at the American Society of Nephrology Kidney Week 2019 Annual Meeting. Abstract is avialable on he conference website at https://www.asn-online.org/education/kidneyweek/archives/.
    • 18 Jan 2018 Results published in a Reata Pharmaceuticals media release
    • 14 Nov 2016 According to a Reata Pharmaceuticals Media Release, based on the data of an analysis assessing risk factors and its risk mitigation strategy for managing acute fluid retention of this trial, FDA approved the Phase 2 program in PAH (LARIAT)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top